leadf
logo-loader
viewPropanc Biopharma, Inc.

Propanc at final stages of completing manufacturing steps to file first clinical trial application

Propanc Biopharma, Inc. (OTCQB: PPCB) CEO James Nathanielsz sat down with Proactive Investors at the BIO CEO and Investor Conference in New York.

The biopharmaceutical company is developing new cancer treatments initially for patients suffering from pancreatic, ovarian and colorectal cancers.

Quick facts: Propanc Biopharma, Inc.

Price: 0.0022 USD

OTCMKTS:PPCB
Market: OTCQB
Market Cap: $337.48 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

ImagineAR and NFL Alumni sign 5 year sponsorship deal helping current and...

ImagineAR (CSE: IP-OTC: IPNFF) CEO Alen Paul Silverrstieen and NFL Alumni International Director Dean Dalton joined Steve Darling from Proactive to share the news that ImagineAR has signed a 5 year deal with NFL Alumni and it’s Academy Program. Silverrstieen talks about how this deal came...

2 hours, 11 minutes ago

2 min read